Neurophet Showcases AI Innovations for Alzheimer's at RSNA 2025 Conference

On December 5, 2025, Neurophet, a pioneering company in artificial intelligence solutions for brain disorders, made a significant impact at the 111th Radiological Society of North America (RSNA) conference, held in Chicago. The event gathered professionals from both the radiology and global medical device sectors, serving as a vital platform for showcasing advanced technologies in the medical field.

Neurophet's highlighted product was its innovative software, Neurophet AQUA AD, which plays a crucial role in monitoring patients undergoing treatment for Alzheimer’s disease. With its ability to analyze brain images accurately through quantitative assessments of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans, Neurophet AQUA AD enables healthcare professionals to track treatment efficacy and observe potential adverse side effects related to anti-amyloid therapies.

During an engaging AI Theater session at the conference, Professor Chong Hyun Suh from Asan Medical Center in South Korea presented compelling clinical use cases demonstrating how Neurophet AQUA AD enhances patient safety. His presentation, titled 'AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy', highlighted the software's advanced capability to detect and quantify Amyloid-Related Imaging Abnormalities (ARIA). Such features address the challenges posed by traditional manual analysis, offering a streamlined approach for clinicians.

The significance of Neurophet AQUA AD was underscored as Professor Suh shared a variety of real-world clinical cases where patients receiving Alzheimer’s treatment developed ARIA, underscoring the potential life-saving advantages offered by AI-driven solutions. His findings draw attention to how AI technology can optimize the clinical effectiveness of anti-amyloid therapies, ensuring patient safety and better health outcomes.

In addition to showcasing Neurophet AQUA AD, Neurophet presented its other solutions, including Neurophet AQUA, which specializes in brain neurodegeneration imaging, and Neurophet SCALE PET, a tool for quantifying PET imaging. The firm also spotlighted the outstanding capabilities of Neurophet AQUA MS, which gained FDA 510(k) clearance last year and serves to analyze brain images of multiple sclerosis patients, providing further evidence of Neurophet's commitment to advancing neuroimaging technologies.

According to Co-CEO Jake Junkil Been, Neurophet AQUA AD is receiving heightened interest from major domestic and international players in the imaging analysis sector. The company aims to leverage partnerships with global medical device firms established during RSNA 2025 to accelerate the uptake of its innovative products across the North American market.

RSNA 2025 represents the largest radiology conference globally, reflecting the current trends and advancements in the medical imaging field, attended by countless radiologists and industry experts. This year's event carried significant weight as it showcased cutting-edge technological innovations that promise to shape future diagnostics and treatment plans.

Founded in 2016, Neurophet’s vision centers on enhancing patient care and treatment outcomes for brain disorders! Continuing to innovate, Neurophet aspires to challenge conventional methods in neuroimaging and treatment analysis, actively working to transform the landscape of brain health with AI technology. Their key products, such as the treatment planning software for electric and magnetic brain stimulation and others, display a robust commitment to improving lives impacted by complex neurological conditions.

Through continued advancements and collaborations, Neurophet aims to become a leader in the realm of brain disorder diagnostics, ultimately contributing positively to the healthcare landscape worldwide. As the company progresses, it remains dedicated to exploring the intricacies of the human brain and pioneering solutions geared towards tackling pressing brain health challenges.